Liquidia (LQDA) Total Non-Current Liabilities (2019 - 2026)
Liquidia's (LQDA) quarterly Total Non-Current Liabilities came in at $284.4 million in Q1 2026, up 67.12% year-on-year from $170.2 million in Q1 2025, and up 3.5% quarter-over-quarter from $274.8 million in Q4 2025.
Liquidia (LQDA) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Liquidia's Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $284.4 million for Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 67.12% year-over-year to $284.4 million in Q1 2026; TTM through Mar 2026 was $284.4 million, a 67.12% increase from a year earlier, with the FY2025 full-year figure at $274.8 million, up 91.32% from the prior year.
- Total Non-Current Liabilities advanced to $284.4 million in Q1 2026 per LQDA's latest filing, from $274.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $284.4 million in Q1 2026 and bottomed at $30.5 million in Q2 2022.
- The 5-year median for Total Non-Current Liabilities is $93.3 million (2024), against an average of $119.4 million.
- Across the five-year window, Total Non-Current Liabilities increased 28.22% in 2023 and surged 137.43% in 2024, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $32.2 million in 2022, then soared by 99.9% to $64.3 million in 2023, then surged by 123.27% to $143.6 million in 2024, then soared by 91.32% to $274.8 million in 2025, then gained by 3.5% to $284.4 million in 2026.
- Per Business Quant, the three latest LQDA Total Non-Current Liabilities figures stand at $284.4 million (Q1 2026), $274.8 million (Q4 2025), and $245.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Liquidia | 7.84 Bn | 7.61 Bn | 121.79 Mn | 284.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 284.41 Mn |
| Dec 31, 2025 | 274.80 Mn |
| Sep 30, 2025 | 245.65 Mn |
| Jun 30, 2025 | 234.25 Mn |
| Mar 31, 2025 | 170.18 Mn |
| Dec 31, 2024 | 143.64 Mn |
| Sep 30, 2024 | 135.17 Mn |
| Jun 30, 2024 | 107.71 Mn |
| Mar 31, 2024 | 93.30 Mn |
| Dec 31, 2023 | 64.33 Mn |
| Sep 30, 2023 | 56.93 Mn |
| Jun 30, 2023 | 54.25 Mn |
| Mar 31, 2023 | 40.67 Mn |
| Dec 31, 2022 | 32.18 Mn |
| Sep 30, 2022 | 30.97 Mn |
| Jun 30, 2022 | 30.46 Mn |
| Mar 31, 2022 | 31.72 Mn |
| Dec 31, 2021 | 22.32 Mn |
| Sep 30, 2021 | 22.26 Mn |
| Jun 30, 2021 | 22.36 Mn |